David Wald
Clinical trials sponsored by David Wald, explained in plain language.
-
Donor NK cells aim to boost cancer fight in new trial
Disease control TerminatedThis early-phase study tests whether giving healthy donor natural killer (NK) cells along with two drugs (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach/esophageal, or blood cancers. The NK cells are meant to attack cance…
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated May 26, 2026 07:44 UTC
-
Speedy new cell therapy takes on lymphoma in early trial
Disease control OngoingThis early-stage study tests a new type of CAR-T cell therapy, made in record time, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose. About 21 adults will take part, and research…
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated May 26, 2026 07:25 UTC
-
Speedy CAR-T cells take on Hard-to-Treat myeloma in first human safety trial
Disease control TerminatedThis early-stage study tests a new type of CAR-T cell therapy for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy, UF-KURE-BCMA, is made from a simple blood draw and has a shorter manufacturing time than standard CA…
Phase: PHASE1 • Sponsor: David Wald • Aim: Disease control
Last updated May 22, 2026 14:02 UTC